XML 43 R36.htm IDEA: XBRL DOCUMENT v3.25.2
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 30, 2013
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue   $ 1,348 $ 998 $ 4,088 $ 26,363
AstraZeneca Agreements [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue   $ 16,400 $ 46,000 53,300 $ 73,100
AstraZeneca Agreements [Member] | U.S./RoW [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Aggregate considerations received       439,000  
AstraZeneca Agreements [Member] | China [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront, non-contingent, non-refundable and time-based payments $ 376,700        
Aggregate considerations received       $ 81,200